Rotavirus (RV), a member of the family Reoviridae, is the leading cause of gastroenteritis in infants and young children . The outer capsid of RV consists of two surface proteins: VP7 (a glycoprotein) and VP4 (a protease-sensitive protein), antibodies against which independently neutralize viral infectivity in a typespecific manner and hence form the basis of a binary (G and P serotypes) classification system (Hoshino et al., 1985; Hoshino & Kapikian, 1996; Offit & Blavat, 1986) . To date, 23 G and 31 P types have been identified (Schumann et al., 2009; Ursu et al., 2009) . Surveillance studies have reported continued prevalence of G1-G4 and G9 RVs worldwide (Bahl et al., 2005; Santos & Hoshino, 2005) . Additionally, high incidences of G12 RVs have recently been reported in neonatal and children with diarrhoea (Rahman et al., 2007; Ray et al., 2007; Sharma et al., 2008) .
Continuous efforts towards development of a safe efficacious vaccine are under way globally. Efficacy of vaccine depends on the immune response generated following vaccination and on protection provided thereafter against the circulating RV genotypes. RV studies in animals have demonstrated immunodominance of various structural (VP2/4/6/7) and non-structural (NSP2/4) proteins during natural infection, thereby suggesting their role in protection (Malik et al., 2008) . Of these, VP6 and NSP4, which represent the non-neutralizing antigens, have demonstrated a role in protection and could be used as potential targets for a subunit vaccine in the future (Choi et al., 2002; Yu & Langridge, 2001 ).
Although the mechanism of virus neutralization is poorly understood, antibodies generated against the two surface proteins, VP4 and VP7, act either in a heterotypic (crossreactive) or a homotypic (serotype-specific) manner against circulating RVs with varying G-P combinations and hence form the basis of vaccine development (Malik et al., 2008) . Currently, both polyvalent and monovalent vaccines have been licensed for use in more than 100 countries worldwide (Ruiz-Palacios et al., 2006; Vesikari et al., 2006) . Rotateq (Merck), is a combination of five human-bovine reassortants, while Rotarix (GSK) is derived from a single serotype G1 human RV strain (Bernstein et al., 1999; Heaton et al., 2005) . In addition, other candidate vaccines are currently in various phases of development Jiang et al., 2008; Kirkwood & Buttery, 2003) . A monovalent neonatal RV strain 116E with G9P [11] specificity is currently undergoing clinical trials in India (Bhandari et al., 2009; Glass et al., 2005) .
The sudden emergence of G12 RVs raises an issue of vaccine efficacy in ongoing clinical trials and more so within the Indian subcontinent where G12 incidence is higher (Rahman et al., 2007) . To the best of our knowledge no serological study in context to G12-infected children has been reported to date. Hence, we conducted a preliminary study to determine the neutralizing antibody (NtAb) response in children infected with G12 RVs and also among those infected with the commonly prevalent genotypes (G1, G2 and G9).
The clinical specimens analysed in this study have been drawn from an earlier study conducted in Delhi during 2002 (Malik et al., 2008 . All children were admitted for RV gastroenteritis and required administration of either Oral Rehydration Solution (Wallace Pharmaceuticals) or intravenous fluids. Briefly, paired sera from 28 RV-positive children were analysed to determine the NtAb response against four reference RV strains: Wa (G1P[8]), DS-1 (G2 P[4]), 116E (G9 P [11] ) and RV024 (G12 P [6] ). The NtAb titres were determined by using ELISA as described previously (Knowlton et al., 1991) . Briefly, 12.5 ml RV lysate (~60 000 focus-forming units ml 21 ) was mixed with equal volume of serially (twofold) diluted paired sera (heat inactivated at 56 u C for 30 min). The plate was then incubated at 37 u C for 1 h for virus neutralization and further diluted by adding 100 ml Iscove's modified Dulbecco's medium (IMDM). Next, the sera-virus mixture (100 ml) was added in duplicate to a monolayer of MA104 cells in wells of a microdilution plate (4 days after subculture). The plates were centrifuged at 1000 g for 1 h at room temperature. Following centrifugation, the wells were washed once with IMDM and 100 ml IMDM (containing 4 mg trypsin ml
21
) was added to each well. The plates were incubated at 37 u C for 16 h. Following incubation, the plates were stored in 220 u C and were freeze-thawed three times. RV antigen in each well was then measured by ELISA. The ELISA plates were coated with rabbit hyperimmune serum generated against human RV and incubated overnight at 4 u C. The cell plates used for neutralization were thawed and 45 ml cell lysate was added to each well on the ELISA plates. This was followed by successive addition of guinea pig hyperimmune serum generated against human RV, peroxidase-conjugated rabbit anti-guinea pig IgG and substrate (O-phenylenediamine with H 2 O 2 ). The plates were then read at A 490 and the values represented absorbance due to RV antigens. The reciprocal of the highest serum dilution that reduced specific absorbency by 60 % was considered its titre. Seroconversion was defined as fourfold or a greater rise in NtAb titre of convalescent phase serum as compared with the acute phase serum. All statistical analysis was done using SPSS version 11.0. Comparison of NtAb titres among children infected with all four infecting RV genotypes (G1/ 2/9/12) was done using Kruskal-Wallis H test, while differences between the groups were determined using Mann-Whitney U test. In the present study, we defined homotypic and heterotypic NtAb responses based on the G genotype of the infecting RV strain. The G and P genotypes of these 28 children were determined previously (Sharma et al., 2008 ).
Tissue culture-adapted human RV strains Wa (G1P[8]), DS-1 (G2P[4]) and 116E (G9P[11]) used in this study were provided by Dr Jon R. Gentsch and Dr Roger I. Glass from Centers for Disease Control and Prevention, Atlanta, USA. The G12P[6] reference strain RV024 used in this study was detected in the faeces of a child with diarrhoea admitted to the Oral Reydration Unit at All India Institute of Medical Sciences and was later culture-adapted. Briefly, RV strain RV024 was isolated in MA104 cells on a roller culture drum in the presence of 0.5 mg trypsin ml 21 essentially according to the method described previously (Kutsuzawa et al., 1982) . All four reference RV strains were quantified by fluorescence focus assay and expressed as fluorescent cell forming units ml 21 as described previously (Knowlton et al., 1991) .
The median age of all 28 children analysed in the present study was 9 months and all of them were between 2 and 28 months of age ( infected children were (i) seroconversion against both G9 and G12 viruses and (ii) seroconversion against all three genotypes, i.e. G1, G9 and G12 (Fig. 1a) . Other patterns of seroconversion were found in no more than two children and comprised NtAb response against either a single or two reference RV strains (Table 1) . Five of these 12, G12P[6]-infected children had NtAb in their acute sera (Table 1) . Of these, one child was 28-months-old and had high NtAb titres (304-2089) against all four RVs, while the other four had relatively lower NtAb titres (19-81) against G9 virus, 116E. Of these four children, two were around 2-3-monthsold, while the other two were relatively older ( Table 1) . The geometric mean NtAb titres against G1P[8] (Wa), G2P[4] (DS-1), G9P[11] (116E) and G12P[6] (RV024) RVs in seven of these 12 children that had no detectable NtAb in the acute serum was 20, 5, 52 and 43, respectively. In addition, approximately eightfold higher NtAb titres were observed in convalescent sera of these seven children against strains belonging to the Wa genogroup (i.e. G1, G9 and G12 RVs) than against strains belonging to the DS-1 genogroup (G2 RVs).
The paired sera from G9P[6]-and G9P[8]-infected children (four each) demonstrated cross-neutralization of G1 and G12 RVs (Fig. 1b) . Six of these eight, seroconverted against 116E, while the remaining two showed a threefold rise in NtAb titres. Heterotypic response was observed in six children against G12P [6] Several studies including ours focusing on in-depth characterization of G12 RVs have demonstrated that the majority of these belong to the Wa genogroup, which represents strains belonging to the G1 and G9 genotypes (Matthijnssens et al., 2008; Rahman et al., 2007; Sharma et al., 2008; Uchida et al., 2006) . Cross-neutralization of G1 and G9 strains among G12-infected children and vice versa observed in the present study is in agreement with previous reports where neutralization of G1 strain was observed in children infected with G9 RVs. Ramachandran et al. (1998) observed 19 % seroconversion against G1 virus (Wa) following G9 infection. Similarly, Brüssow et al. (1991) demonstrated that G1-infected children generated heterotypic response against G3, G4 and G9 RVs. There were two children infected with G2 RV who seroconverted against G9 virus (116E), contradicting the general hypothesis that sera of G2-infected children do not seroconvert against G1 and G9 viruses (Zheng et al., 1988) . However, isolated cases of G2-infected children seroconverting against G1 viruses (which belong to the same genogroup as G9) have been observed in the past (Arias et al., 1994) .
Additionally, the present study observed relatively lower homotypic (versus RV024) NtAb response among G12P[6]-infected children as compared with other infecting genotypes (G1, G2 and G9 or due to previous exposure depending upon the age, as five of these 12 children were between 2 and 28 months of age. Asymptomatic and symptomatic infections in neonates and children with G9P[6] RV is a common observation in Indian nurseries and community settings, and hence it may also be possible that antibodies generated against the P[6] VP4 antigen during earlier infection may affect immunogenecity of G12P[6] RV (Bahl et al., 2005; Ray et al., 2007) . Additionally, lower immunogenicity may be an intrinsic property of the virus itself and could be due to the strain-to-strain variation. Such observations have been reported in the past. Ward et al. (1990) observed consistently high NtAb titres to G1 and G3 serotypes, while low titres were observed for G2 and G4 viruses (Ward et al., 1990) . In addition, the lower immunogenicity could be restricted within the G12 genotype itself. Whether such phenomenon is genotype specific or due to strain-to-strain variation within the G12 isolates needs further investigation.
In contrast, the homotypic response generated in terms of geometric mean NtAb titres following G9 RV infection was relatively high. This is in agreement with the previous studies where immunogenicity of neonatal G9 RVs was evaluated (Bhan et al., 1993) . In that study, 116E like G9 strains were found to confer protection against severe RV diarrhoea and also elicited potent immune response thereby confirming its immunogenicity. The recently conducted vaccine trial with the 116E strain also demonstrated high immunogenicity among the vaccinated children (Bhandari et al., 2006 (Bhandari et al., , 2009 Neutralizing antibody response to G12 RV G12 RVs following G9 genotype infection further strengthens the fact that a G9-based vaccine may provide broader coverage against the circulating RV genotypes.
Additionally, 13 children had detectable amounts of NtAbs in their acute sera. Of these, two had NtAbs against all four RVs. Both children were older than 12 months of age and the presence of antibodies is most conceivable as a result of a previous infection. However, all remaining children had NtAb against the G9 virus only. This could be either due to a previous exposure or could be attributed to the presence of maternal antibodies. We previously reported G9 RVs to be prevalent in the Indian nurseries and were a source of asymptomatic infection in newborns (Das et al., 1994; Ray et al., 2007) . In addition, another study from Western India observed relatively high percentages of NtAb against G9 RVs (Ray & Kelkar, 2004) . Similarly, Brüssow et al. (1991) also observed high prevalence of G9 antibodies in European and Central American children (Brüssow et al., 1991) .
Finally, the present study has helped in evaluating the extent of cross-neutralization observed against the reference RV strains following infection with G12 genotype and vice versa. One of the limitations of the present study was its inability to evaluate the role of individual surface proteins (VP7 and VP4) and also simultaneously address the issue of primary and secondary infections. In addition, further confirmative studies should be conducted on a relatively larger number of subjects.
In conclusion, the study demonstrated cross-neutralization of reference RV strains (G1 and G9) belonging to the Wa genogroup following G12 infection and no or relatively low neutralization against strains belonging to the DS-1 genogroup (G2). This observation, thus suggests that a monovalent vaccine based on the Wa genogroup may confer protection against G12 RVs and future studies should be conducted to address this issue.
